Business Insider

Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma ...

JERUSALEM, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-emitters cancer therapy Alpha DaRT®, ...
MarketWatch

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT(R) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

The MarketWatch News Department was not involved in the creation of this content. - Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular ...
Seeking Alpha

Alpha Tau Enters Into Long-Term Lease of Site in New Hampshire for Second U.S. Manufacturing Facility

Oct. 30, 2023 8:30 AM ETAlpha Tau Medical Ltd. (DRTS) About Alpha Tau Medical Ltd. Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential ...
Nasdaq

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

JERUSALEM, April 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has ...
Nasdaq

Alpha Tau Medical Ltd. CFO Raphi Levy to Present at Jefferies Global Healthcare Conference on June 5, 2025

Mr. Levy will be available for 1x1 investor meetings. Please reach out to your Jefferies representative to schedule. About Alpha Tau Medical Ltd. Founded in 2016, Alpha Tau is an Israeli oncology ...
Seeking Alpha

Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update

EPS of -$0.12 beats by $0.01 In April, Alpha Tau announced the completion of a $36.9 million registered direct financing from, and strategic marketing alliance with, an affiliate of Oramed ...
Yahoo Finance

Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead

Following an incredibly productive 2025, culminating in several significant announcements in recent weeks, I wish to share with you an updated comprehensive picture of Alpha Tau’s position and ...
Business Insider

Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)

- Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and ...